Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2025-12-24 @ 5:39 PM
NCT ID:
NCT02041468
Eligibility Criteria:
Inclusion Criteria:
* Patients with histologically confirmed locally advanced or metastatic NSCLC
* Presence of the ALK-fusion oncogene (ALK+) as determined using a validated testing platform
* Measurable disease according to RECIST v. 1.1
* Planned or ongoing treatment with crizotinib
* Signed and dated IRB-approved informed consent document
* Ability to read and understand English or French
* 18 years of age or older
Exclusion Criteria:
* Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease.
* Unwilling to provide consent for genetic studies of the tumor, whole blood, or plasma specimens.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02041468
Study Brief:
Protocol Section:
NCT02041468